Karyopharm Therapeutics (NASDAQ:KPTI) Upgraded to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Karyopharm Therapeutics (NASDAQ:KPTI) from a strong sell rating to a hold rating in a report published on Saturday.

Several other research firms have also recently weighed in on KPTI. Royal Bank Of Canada lowered their target price on Karyopharm Therapeutics from $30.00 to $19.00 and set an “outperform” rating on the stock in a research note on Tuesday, November 4th. Robert W. Baird decreased their price target on shares of Karyopharm Therapeutics from $25.00 to $21.00 and set an “outperform” rating for the company in a report on Thursday, October 9th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Karyopharm Therapeutics in a research note on Wednesday. Piper Sandler reiterated an “overweight” rating and issued a $12.00 target price (down previously from $15.00) on shares of Karyopharm Therapeutics in a research report on Thursday, October 9th. Finally, HC Wainwright raised shares of Karyopharm Therapeutics from a “neutral” rating to a “buy” rating and set a $15.00 target price for the company in a research note on Monday, October 13th. Five equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $15.40.

Karyopharm Therapeutics Price Performance

NASDAQ KPTI traded down $0.06 on Friday, hitting $5.16. 91,770 shares of the stock were exchanged, compared to its average volume of 150,533. The company’s 50-day moving average price is $6.18 and its two-hundred day moving average price is $5.39. Karyopharm Therapeutics has a 52-week low of $3.51 and a 52-week high of $14.24. The company has a market capitalization of $44.74 million, a price-to-earnings ratio of -0.36 and a beta of 0.35.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its earnings results on Monday, November 3rd. The company reported ($3.82) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($3.30) by ($0.52). The firm had revenue of $44.04 million during the quarter, compared to the consensus estimate of $39.56 million. Karyopharm Therapeutics has set its FY 2025 guidance at EPS. Equities analysts predict that Karyopharm Therapeutics will post -0.71 EPS for the current fiscal year.

Hedge Funds Weigh In On Karyopharm Therapeutics

Several institutional investors have recently bought and sold shares of KPTI. Baird Financial Group Inc. bought a new stake in shares of Karyopharm Therapeutics during the 2nd quarter worth about $45,000. XTX Topco Ltd acquired a new stake in Karyopharm Therapeutics in the 2nd quarter worth approximately $56,000. Bridgeway Capital Management LLC bought a new stake in Karyopharm Therapeutics during the second quarter worth approximately $163,000. Silverback Asset Management LLC grew its holdings in Karyopharm Therapeutics by 40.0% during the second quarter. Silverback Asset Management LLC now owns 70,000 shares of the company’s stock valued at $302,000 after purchasing an additional 20,000 shares during the last quarter. Finally, T. Rowe Price Investment Management Inc. acquired a new position in Karyopharm Therapeutics during the first quarter valued at approximately $523,000. 66.44% of the stock is currently owned by institutional investors.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).